HIV testing disparities among black MSM in the Southern U.S.; reasons for non-adherence in a vaginal HIV prevention ring trial; the importance of PrEP despite successful HIV treatment; inaccurate antiretroviral usage rates in Africa.
Fewer health care visits for PrEP recipients; sexual behavior in the U=U era; HIV and bone issues in women; how Medicaid enrollment gaps affect HIV treatment success.
The risk of transmitting HIV through the breastmilk of virally suppressed women in high-income countries is not known.
Lower CD4, higher viral load in the U.S. South; HIV testing among U.S. heterosexuals; heightened seroconversion risk around childbirth; predicting success for long-acting, injectable PrEP.
Adherence to HIV care visits was associated more with mental health conditions before starting antiretroviral treatment than with recent depressive symptoms, while a detectable viral load was related to such symptoms.
Missed opportunities to prescribe PrEP to at-risk people; long-term viral suppression reduces cancer risk; sexual health clinics and linkage to care; neurocognitive benefits of low-dose hydrocortisone therapy for women.
HIV self-testing vs. professional HIV testing; the most effective influenza vaccine strategies for people with HIV; how age can affect flu vaccine efficacy; early HIV treatment and CD4:CD8 ratio normalization.
Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.
Housing, social support, and HIV transmissibility among people who use drugs; concerning hepatitis C incidence trends in France; frailty among people aging with HIV; untreated HIV and brain atrophy.